BR112022012284A2 - Combinações - Google Patents

Combinações

Info

Publication number
BR112022012284A2
BR112022012284A2 BR112022012284A BR112022012284A BR112022012284A2 BR 112022012284 A2 BR112022012284 A2 BR 112022012284A2 BR 112022012284 A BR112022012284 A BR 112022012284A BR 112022012284 A BR112022012284 A BR 112022012284A BR 112022012284 A2 BR112022012284 A2 BR 112022012284A2
Authority
BR
Brazil
Prior art keywords
combinations
disease
compounds
condition
inhibitor
Prior art date
Application number
BR112022012284A
Other languages
English (en)
Inventor
Abdi Samatar Ahmed
Izadi Hooman
Qinhua Huang Peter
Robert Pinchman Joseph
Duane Bunker Kevin
Donate Fernando
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Publication of BR112022012284A2 publication Critical patent/BR112022012284A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glass Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)

Abstract

INCORPORAÇÃO POR REFERÊNCIA A QUAISQUER PEDIDOS DE PRIORIDADE. São divulgadas no presente documento combinações de compostos para o tratamento de uma doença ou afecção, tal como câncer. Uma combinação de compostos para o tratamento de uma doença ou condição pode incluir um inibidor de Bcl-2 e um inibidor de WEE1, juntamente com sais farmaceuticamente aceitáveis de qualquer um dos anteriores.
BR112022012284A 2019-12-20 2020-12-16 Combinações BR112022012284A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962952059P 2019-12-20 2019-12-20
PCT/US2020/065406 WO2021127041A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (1)

Publication Number Publication Date
BR112022012284A2 true BR112022012284A2 (pt) 2022-08-30

Family

ID=76478152

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012284A BR112022012284A2 (pt) 2019-12-20 2020-12-16 Combinações

Country Status (12)

Country Link
US (1) US20230065577A1 (pt)
EP (1) EP4069234A4 (pt)
JP (1) JP2023508331A (pt)
KR (1) KR20220119427A (pt)
CN (1) CN115023229A (pt)
AU (1) AU2020404995A1 (pt)
BR (1) BR112022012284A2 (pt)
CA (1) CA3165468A1 (pt)
IL (1) IL294081A (pt)
MX (1) MX2022007625A (pt)
TW (1) TW202135814A (pt)
WO (1) WO2021127041A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226263A1 (en) * 2020-05-07 2021-11-11 Recurium Ip Holdings, Llc Combinations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155752B1 (en) * 2007-04-25 2018-09-19 Merck Sharp & Dohme Corp. Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor
PT2477628E (pt) * 2009-09-15 2014-11-25 Merck Sharp & Dohme Preparação de formas de hemihidrato cristalino de dihidropirazolopirimidinona
MX369518B (es) * 2012-08-16 2019-11-11 Novartis Ag Combinacion de inhibidor de p13k e inhibidor de c-met.
PL2925888T3 (pl) * 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
US11613545B2 (en) * 2017-11-01 2023-03-28 Wuxi Biocity Biopharmaceutics Co., Ltd. Macrocyclic compound serving as Wee1 inhibitor and applications thereof
AU2019207608B2 (en) * 2018-01-10 2024-03-28 Recurium Ip Holdings, Llc Benzamide compounds
WO2019169065A2 (en) * 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same

Also Published As

Publication number Publication date
CN115023229A (zh) 2022-09-06
CA3165468A1 (en) 2021-06-24
KR20220119427A (ko) 2022-08-29
AU2020404995A1 (en) 2022-07-14
EP4069234A4 (en) 2024-01-03
MX2022007625A (es) 2022-08-16
WO2021127041A1 (en) 2021-06-24
JP2023508331A (ja) 2023-03-02
IL294081A (en) 2022-08-01
US20230065577A1 (en) 2023-03-02
EP4069234A1 (en) 2022-10-12
TW202135814A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
BR112019002275A2 (pt) inibidores aminopirimidina de ssaos
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
BR112017026159A2 (pt) inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer
BR112019006047A2 (pt) compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica
BR112018068565A2 (pt) combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos
BR112016030541A2 (pt) métodos para o tratamento de infecções fúngicas
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112022012281A2 (pt) Combinações
BR112022012280A2 (pt) Combinações
CO2021014008A2 (es) Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento
EA202191519A1 (ru) Модуляторы trex1
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
BR112019024322A2 (pt) Compostos e composições terapêuticos e métodos de uso dos mesmos
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112017000132A2 (pt) composto, composição farmacêutica e método de tratamento ou prevenção de uma doença responsiva à inibição da atividade de pi3k
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.
BR112022012283A2 (pt) Combinações
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112015028516A2 (pt) tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112022012284A2 (pt) Combinações